Beyond_Air Nasdaq Listing Extension Granted
Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
The extension granted by Nasdaq-100 provides q.beyond with crucial time to address its listing compliance, potentially preventing delisting and stabilizing investor confidence. The proposed reverse stock split, if approved, aims to increase q.beyond's stock price, which could positively impact its market valuation and attract investors.
q.beyond, a medical device and biopharmaceutical company, has received an extension from the Nasdaq-100 Hearings Panel to regain compliance with Nasdaq-100's bid price rule by July 31, 2026. The company's stock has been trading below the minimum bid price requirement. To address this, q.beyond's shareholders will vote on a proposal to authorize a reverse stock split at a special meeting on June 18, 2026. CEO Robert Goodman Jr. expressed confidence in the company's plan to regain compliance while continuing to focus on commercial execution and advancing its nitric oxide platform. q.beyond is also compliant with all other Nasdaq-100 listing requirements. In other recent developments, q.beyond secured a national group purchasing agreement for its inhaled nitric oxide therapy and announced a leadership change with Robert Goodman Jr. becoming CEO. Additionally, its subsidiary Beyond Cancer Limited reported early survival data from a Phase 1 trial for solid tumors, and q.beyond terminated a proposed transaction to sell its NeuroNOS subsidiary to Mapp Biopharmaceutical.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard